FDA approves Dova's drug

The U.S. Food and Drug Administration has approved Durham-based Dova Pharmaceuticals' first drug. The approval is for avatrombopag, which treats low platelet count in patients with chronic liver disease. According to Dova, with about 70,000 patients with CLD suffering from severe low platelet count in the U.S., the company’s lead drug is slated to be an alternative to more invasive platelet transfusions that present the possibility of infection, among other risks. Platelet count needs to be increased…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news